This trial is evaluating whether Olaparib will improve 2 primary outcomes and 2 secondary outcomes in patients with Stage IIB Pancreatic Cancer AJCC v8. Measurement will happen over the course of Changes in tumor biology from baseline (i.e., Day 0) and on-treatment biopsy (i.e., 10 days from start of study intervention).
This trial requires 80 total participants across 4 different treatment groups
This trial involves 4 different treatments. Olaparib is the primary treatment being studied. Participants will be divided into 4 treatment groups. There is no placebo group. The treatments being tested are in Phase < 1 and are in the first stage of evaluation with people.
"Early diagnosis and well-controlled treatment are a prerequisite for a normal life. In some patients, the malignant cells remain in the body but are effectively controlled by the treatment. Patients with the cured disease seem to be free from the disease for the period available in their life. This fact and their good quality of life, may be used to convince the patients to consider palliative care." - Anonymous Online Contributor
"Findings from a recent study shows that most cases of cancer of pancreas are diagnosed among older people. Also, it demonstrates that cancer of pancreatic duct is the most common cause of cancer of the pancreas." - Anonymous Online Contributor
"Cancer of pancreas has the highest number of fatal cases in the country. answer: Cancer of pancreas has very high fatal case count in Nepal. This is due to a high number of chronic diseases and lack of adequate care. Cancer of pancreas is not included in the basic health policy of Nepal. It is a vital problem, as it has significant financial burden, and high rate of death and other health problems. More focus needs to be given to cancer of pancreas." - Anonymous Online Contributor
"The common treatments for cancer of pancreas are summarized in this article. Differential use of chemotherapeutic agents was observed in tumors of different histologies. As in other malignancies, chemotherapeutics have been used first line with response rates of 23-65%. Radiation therapy is often used for tumors with advanced lesions and for locoregional control of these metastatic lesions. Chemo-sensitive tumors are often treated with radiation therapy or other chemotherapeutic drugs, with response rates being as high as 50-96%." - Anonymous Online Contributor
"The pancreatic cancer risk associated with CPRA is not affected by any modifier, but the disease in patients with CPRA is significantly related to the age of onset and tumor size." - Anonymous Online Contributor
"The signs of pancreatic carcinoma include weight loss, poor appetite, dullness (pale appearance) and malaise (tired) or pain. Decreased jaundice, with no specific abnormalities on physical examination, may suggest the diagnosis. Abdominal mass may indicate a cancer of the pancreas or an acute pancreatitis, and patients should be questioned about a family history of pancreatic cancer. Diagnosis often requires testing procedures such as computed tomography (CT) scan or magnetic resonance imaging (MRI). These procedures have good sensitivity and specificity and are usually performed after a biopsy." - Anonymous Online Contributor
"There was a significant lack of research involving olaparib. There is little evidence for the benefits of olaparib in specific subgroups with advanced pancreatic cancer. A trial with olaparib is ongoing for women with a HER2 positive and/or PgR negative breast cancer. [Astrofund." - Anonymous Online Contributor
"In this phase 2b study comparing carboplatin/bolus liposomal doxorubicin plus olaparib versus carboplatin/bolus liposomal doxorubicin plus doxorubicin in people with metastatic/high risk epithelial ovarian cancer (EOC), the authors identified no significant differences in grade rash/fever, or serious cutaneously related events between the two treatment groups. Neither common side effects of olaparib nor anemia prevented dose escalation. The safety profile of olaparib is not expected to be driven by its interaction with carboplatin/liposomal doxorubicin." - Anonymous Online Contributor
"Olaparib is a highly effective and well-tolerated chemotherapeutic agent in the treatment of ovarian cancer, and has been shown to be active against platinum refractory and platinum-sensitive recurrent high-grade serous epithelial ovarian cancer. Olaparib is well-tolerated at both standard doses and at both dosing intervals." - Anonymous Online Contributor
"Pancreatic cancer is a rare disorder, however, it is related with complications including gallstone, pancreatitis, diabetes, or bleeding. Diabetes, especially type 2 diabetes mellitus, is not strongly correlated but it is related with pancreatitis. Moreover it is correlated with chronic alcohol abuse as well as smoking and also high blood pressure." - Anonymous Online Contributor
"We thought that there will be more advancements in research, and more advances in treatment options for patients of pancreatic cancer through more studies. There may also be new research on pancreatic cancer itself, which will help us understand better the mechanisms and the cause of the disease." - Anonymous Online Contributor
"Although the percentage of metastatic CDA patients with an advanced-stage disease increased, they still had a relatively good prognosis compared to those without cancer invasion in the pancreatic ducts. More intensive efforts are recommended to perform clinical trials for metastatic CDA patients with a good performance status and good life expectancy." - Anonymous Online Contributor